consultancy Daneris Fernández, CEO and president of DGF Consulting Group, outlines the firm’s services that help Latin American companies enter Puerto Rico as well as its focus on hospital consulting. What was the inspiration for your change of direction from Merck to DGF? My last position in Merck was as vice…
IMS IMS Health recently released its World Review 2015. The new general manager of North Latin America shares the company’s assessment on the performance of the Mexican pharmaceutical market for 2014, what trends are shaping the industry as well as the moderate, yet positive outlook for 2015. How would you assess…
association The industry of medical devices is still not very well understood. Pablo Dávila shared with us his overview on the Mexican market, how the Mexican Association of Innovative Medical Device Industries (AMID) is interested on putting the sector on the map. Could you please tell us a bit more about…
MSD The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15 percent growth year on year, why 2014 has been a tough year for the sector and how MSD is focusing…
Janssen The country manager of one of the foremost providers of sustainable and integrated healthcare solutions describes the sorts of local adaptations that need to be enacted when launching a product on the Romanian market. He also speaks extensively about the state of the local medical device market and its likely future potential. Can…
Lilly A recent arrival from China, Lilly’s Turkey MD Daniel Lucas assesses the country’s healthcare system and raises key questions about the sustainability of the system at large going forward, and the authorities’ approach to reform. You came to Turkey in October after more than four years in China. What is your…
MSD MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy and incentivizing CRM use to improve operational efficiencies. You took over last year as managing director of MSD Turkey, after…
GSK GSK’s VP and Area GM Pharmaceuticals, Turkey and Caucasus, and chairman of Turkey’s innovative pharmaceutical association, discusses the effectiveness of the government’s current strategy for reducing the trade deficit in the pharmaceutical industry, and the need for the industry and government to approach all discussions with a partnership mentality. Do…
Biocodex Biocodex’s new general manager gives an overview of the affiliates ‘new deal’ program, and how the company has adjusted its approach to better fit the contemporary Turkish environment. What attracted you to Biocodex Turkey? What are your impressions of the business so far? Biocodex made the right decision in starting…
Daiichi Sankyo The general manager of Daiichi Sankyo Turkey discusses his affiliate’s expansion into a regional hub, current strategies for growth in the Turkish market, and the keys behind his affiliates multiple ‘great place to work’ awards. In 2012, you had made it a goal to develop the Turkish affiliate into a regional…
Ferring The general manager of a speciality biopharma business challenges lawmakers to regard health spending not as a cost but as an investment and reveals how women’s healthcare and fertility treatment can become showcase examples in making Romanian healthcare sustainable. Back in 2011, when we asked you about Ferring’s priorities in…
Pfizer One of the new cohort of country managers speaks out about Romania’s blossoming potential as a manufacturing hub and explains in detail how his firm is diverting product lines form elsewhere in Europe and relocating them in Cluj so as to exploit what he sees as a real competitive advantage.…
See our Cookie Privacy Policy Here